Molomics advances the search for structurally novel small molecule therapeutics by Artificial Intelligence (AI) through integrating it with Human Collective Intelligence (HCI). As molecules are designed collaboratively in silico between machine and humans, we expect that our drug candidates are more efficacious and safer, increasing the success rates in clinical development.
It is very challenging to determine highly effective and safe therapeutics. Molomics Technology overcomes this challenge by integrating Humans Collective Intelligence (HCI) of teams with Artificial Intelligence (AI) to collaboratively design high potential drug candidates with diverse structures in real-time. The process generates quality drug information by machine learning methods and human knowledge to come up with optimal drug candidates.
(e.g. Machine Learning)
Consensus Decision Making
Molomics focuses on Parkinson's Disease (PD). Our current programs address Levadopa Induced Dyskinesia (LID). PD_LID_1 works on a partially clinically validated target. PD_LID_2 focuses on a dual drug, binding two targets with synergistic effects.
Molomics wants to partner with selected biotechs or pharma companies in their disease area of interest. Molomics drug design approach, driven by its proprietary technology, is further re-inforced by state of the art project management: